Clinical Trial Update: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV [Phase 3]

View source ↗

Summary

Phase 3 study evaluating pegylated interferon lambda-1a with ribavirin and daclatasvir for chronic hepatitis C in treatment-naïve patients co-infected with HIV;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Pegylated interferon lambda-1a (pegylated interferon lambda-1a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C Infection | Phase 3 | Status: TERMINATED | Results posted: 2023-06-13